Christian Hollweg

Mr. Hollweg's recent experience includes representing:

• CG Oncology, an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, in its US$105 million Series F financing, co-led by Foresite Capital and TCGX, with participation from new investors Avidity Partners, BFG Partners, and Janus Henderson Investors and certain existing investors; and earlier CG Oncology’s US$120 million Series E financing, co-led by ORI Capital, Longitude Capital and Decheng Capital, with participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge Group, and Senora Capital
• Mineralys Therapeutics, focused on hypertension therapies, in its US$118 million Series B financing led by RA Capital and Andera Partners
• Clarify Health, a cloud analytics and value-based payments platform company, in its US$150 million Series D financing, led by SoftBank Vision Fund 2, with participation from BlackRock and Memorial Hermann Health System
• Molecular Assemblies, developing an enzymatic DNA synthesis technology, in its US$29 million Series B financing, with participation from Casdin Capital, Agilent Technologies, iSelect Fund, Codexis, LYFE Capital, and Argonautic Ventures
• NewLimit, a biotechnology company focused on combatting aging through cell biology, genomics, machine learning and cellular reprogramming, in its US$40 million Series A financing, led by Dimension, Founders Fund, and Kleiner Perkins
• Medallion, the modern provider management platform, in its US$35 million Series C financing, led by Spark Capital and GV (formerly Google Ventures), with participation from new investor Salesforce Ventures and existing investors including Sequoia Capital, Optum Ventures, BoxGroup, and Elad Gil
• Convex, the software platform leading the commercial services industry’s digital-first revolution, in its US$39 million Series B financing, led by Fifth Wall, Emergence Capital and GGV, with participation from UP2398, 1984 Ventures, Soma Capital, and former ServiceMax CEOs Scott Berg and David Yarnold
• Zerigo Health, which delivers the only connected light therapy solution for treating chronic skin conditions at home or on the go, in its US$43 million Series B financing with participation from 7wireVentures, SV Health Investors, H.I.G. Capital, Bluestem Capital, General Catalyst, Dragoneer, Cigna Ventures, Leverage Health Solutions, and Leaps by Bayer Ocelot Bio, focused on liver disease, in its US$36 million Series A financing, led by Venrock Partners, Vivo Capital, and RA Capital
• Lead investor Avenir Growth in the US$111 million Series B financing of Chile-based Xepelin, a provider of B2B payments and financial services for SMBs in Latin America, the largest Series B financing round in Chile’s history as of such time